Search results
3 Magnificent Stocks That Are Passive Income Machines
Motley Fool via Yahoo Finance· 9 hours agoAbbVie expects to return to solid sales growth next year. It projects a high single-digit revenue...
Earnings call: Alcon reports record Contact Lens sales, optimistic outlook By Investing.com
Investing.com· 1 hour agoThe company experienced record sales in its Contact Lens business and anticipates FDA approval for...
UK jobs data supports BoE rate cut, and Vodafone shares rise after earnings
The Forex Market· 12 hours agoThe labour market data in the UK for March and April suggests that the jobs market is softening, the...
EU member states sign off on stricter migration reforms
dpa international via Yahoo News· 5 hours agoEU ministers on Tuesday gave their final approval to a massive overhaul aimed at tightening the...
How to save thousands on your home purchase with an assumable mortgage | ARLnow.com
ARLnow.com· 55 minutes agoAssumable mortgages offer a fantastic opportunity to save thousands on your mortgage, especially in...
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by...
Benzinga· 2 days agoThe approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, including robust intracranial responses Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today
Niagara Falls School District must abide by negative tax cap: 'It's just unrealistic'
The Buffalo News· 1 day agoNiagara Falls City School District voters have a history of approving budgets, and approval rates of...
Meralco rates up in May - BusinessWorld Online
BusinessWorld· 3 hours ago(Meralco) will see higher electricity bills this month due to the increase in generation charge. In a statement on Tuesday, Meralco said that the overall...
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
Pharmaceutical Technology via Yahoo Finance· 1 day ago“There is a significant unmet need for these patients...an August 2023 data update for TRIDENT-1,...
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 6 hours agoKeytruda sales are gaining from continued strong momentum in metastatic indications and rapid uptake...
